1200406-33-2

Upstream product

• 1308320-06-0 C₃₀H₃₉ClO₇ 
• 109-89-7 diethylamine 

Downstream Products

• 1200406-81-0 [5-[1-(R)-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-2-phosphonooxybenzyl]-(diethyl)-[[[11β,16α]-[16,17-((R)-cyclohexylmethylene)bis(oxy)]-11-hydroxypregna-1,4-diene-3,20-dion-21-oxy]-carbonylmethyl]ammonium chloride 
• 1313485-83-4 (R)-[5-[2-[9-[4-(biphenyl-2-ylcarbamoyloxy)piperidin-1-yl]nonylamino]-1-hydroxyethyl]-2-phosphonooxybenzyl]-(diethyl)-[[11β,16α]-[[15,16-((R)-cyclohexylmethylene)bis(oxy)]-11-hydroxypregna-1,4-diene-3,20-dion-21-yl]carbonylmethyl]ammonium trifluoroacetate 

Relevant academic research and scientific papers

CORTICOSTEROID-BETA-AGONIST-MUSCARINIC ANTAGONIST COMPOUNDS FOR USE IN THERAPY

The instant invention relates to new chemical entities which comprise corticosteroids, phosphorylated β-agonists and muscarinic (M3) antagonists for use in therapy and compositions comprising and processes for preparing the same.

CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY

New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.